Search results
Author(s):
Masahiro Natsuaki
Added:
7 months ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111).
In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at…
View more
Author(s):
Marco Valgimigli
Added:
1 year ago
ESC Congress — Prof Marco Valgimigli (Cardiocentro Ticino Foundation, CH) shares the findings from an individual patient data meta-analysis from the PANTHER collaborative initiative that looked at P2Y12i or aspirin monotherapy as secondary prevention in patients with coronary artery disease.
The six randomised trials included in the study were CAPRIE, DACAB, TiCAB, GLASSY, CADET, STAMI. The aim…
View more
Update on DAPT
Author(s):
Robert F Storey
Added:
4 years ago
Video
Author(s):
Dipti Itchhaporia
Added:
4 months ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity…
View more
Author(s):
Andrew Archbold
Added:
3 years ago
Patients who undergo coronary artery stenting require dual antiplatelet therapy (DAPT) in order to reduce their risk of stent thrombosis. Long-term oral anticoagulation (OAC) is indicated for the primary and secondary prevention of thrombotic events in patients with atrial fibrillation (AF), mechanical heart valves, intra-cardiac thrombus, venous thromboembolic disease and some hypercoagulable…
View more
AF, Stent and Anticoagulant
Author(s):
Balen Abdulrahman
,
Richard J Jabbour
,
Nick Curzen
Added:
10 months ago
Article
Author(s):
Antonio Greco
,
Claudio Laudani
,
Carla Rochira
,
et al
Added:
1 year ago
Author(s):
Davide Cao
Added:
2 years ago
Dr Davide Cao (Icahn School of Medicine at Mount Sinai, US) discusses the key results and impact on clinical practice of the pre-specified analysis of the TWILIGHT trial presented at ESC Congress 2021.
TWILIGHT-HBR evaluated the effects of ticagrelor monotherapy versus ticagrelor (Brilinta) plus aspirin on bleeding and ischemic outcomes in a contemporary ARC-defined HBR population undergoing…
View more
Author(s):
Kevin S Tang
,
Shoujit Banerjee
,
George Tang
,
et al
Added:
4 months ago
Author(s):
Sri Raveen Kandan
,
Thomas W Johnson
Added:
3 years ago
Antiplatelet Therapy
Current guidelines support the early administration of oral antiplatelet agents upstream of angiographic assessment and intervention.1 Aspirin is commonly given by the first medical contact and additional oral antiplatelet drugs are administered on arrival in hospital (see Figure 1).
Aspirin
The efficacy of aspirin in acute ST-segment elevation myocardial infarction (STEMI)…
View more